Unknown

Dataset Information

0

Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study.


ABSTRACT: OBJECTIVES:Comparison of two doses of bio-optimized Curcuma longa extract (BCL) in the management of symptomatic knee osteoarthritis (OA). METHODS:A prospective, randomized, 3-month, double-blind, multicenter, three-group, placebo-controlled trial assessing Patient Global Assessment of Disease Activity (PGADA) and serum sColl2-1, a biomarker of cartilage degradation, as co-primary endpoints. Pain on visual analog scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS), and paracetamol/non-steroidal anti-inflammatory drug (NSAID) consumption were used as secondary endpoints. RESULTS:One hundred fifty patients with knee OA were followed for 90?days. Low and high doses of BCL showed a greater decrease of PGADA than placebo. Analysis of sColl2-1 showed in the placebo and BCL low-dose groups, but not in the BCL high-dose group, a transient but non-significant increase of sColl2-1 between T0 and T1. Thereafter, in all groups, sColl2-1 decreased between T1 and T3 (all p?

SUBMITTER: Henrotin Y 

PROVIDER: S-EPMC6661105 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study.

Henrotin Y Y   Henrotin Y Y   Malaise M M   Wittoek R R   de Vlam K K   Brasseur J-P JP   Luyten F P FP   Jiangang Q Q   Van den Berghe M M   Uhoda R R   Bentin J J   De Vroey T T   Erpicum L L   Donneau A F AF   Dierckxsens Y Y  

Arthritis research & therapy 20190727 1


<h4>Objectives</h4>Comparison of two doses of bio-optimized Curcuma longa extract (BCL) in the management of symptomatic knee osteoarthritis (OA).<h4>Methods</h4>A prospective, randomized, 3-month, double-blind, multicenter, three-group, placebo-controlled trial assessing Patient Global Assessment of Disease Activity (PGADA) and serum sColl2-1, a biomarker of cartilage degradation, as co-primary endpoints. Pain on visual analog scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS), an  ...[more]

Similar Datasets

| S-EPMC8590273 | biostudies-literature
| S-EPMC8202067 | biostudies-literature
| S-EPMC5854386 | biostudies-literature
| S-EPMC6723939 | biostudies-literature
| PRJNA122729 | ENA
| PRJNA610001 | ENA
| PRJNA748946 | ENA
| PRJNA135353 | ENA
| PRJNA270561 | ENA